Literature DB >> 8343170

Tumor cell retention of antibody Fab fragments is enhanced by an attached HIV TAT protein-derived peptide.

D C Anderson1, E Nichols, R Manger, D Woodle, M Barry, A R Fritzberg.   

Abstract

Two peptide analogs of the 37-62 sequence region of the HIV TAT protein bind tightly to the surface of A431 breast carcinoma cells. After conjugation to either of two poorly internalized anti-tumor antibody Fab fragments, the analogs enhanced the in vitro cell surface retention and internalization of the Fab fragments to the level of the whole antibodies. This was at the expense of some binding specificity in the case of 1.6 peptides/NRLU-10 Fab, but not in the case of 1.1 peptides/Fab. Enhanced retention may occur by enhanced bivalent binding of the Fab fragments. The internalized fraction of free peptide, but not of the Fab conjugates, is enhanced by chloroquine. The conjugates which were less specific for tumor cell binding may be useful for enhanced retention/internalization of specifically acting agents, for use at specific sites of injection, or against pre-separated target cell populations, while the more specific conjugate may be of interest for further development.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8343170     DOI: 10.1006/bbrc.1993.1903

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  Targeting antibodies to the cytoplasm.

Authors:  Andrea L J Marschall; André Frenzel; Thomas Schirrmann; Manuela Schüngel; Stefan Dübel
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

2.  Transduction of the scorpion toxin maurocalcine into cells. Evidence that the toxin crosses the plasma membrane.

Authors:  Eric Estève; Kamel Mabrouk; Alain Dupuis; Sophia Smida-Rezgui; Xavier Altafaj; Didier Grunwald; Jean-Claude Platel; Nicolas Andreotti; Isabelle Marty; Jean-Marc Sabatier; Michel Ronjat; Michel De Waard
Journal:  J Biol Chem       Date:  2005-01-14       Impact factor: 5.157

3.  Cell-penetrating peptides and antibodies: a new direction for optimizing radioimmunotherapy.

Authors:  Maneesh Jain; Ganesh Venkatraman; Surinder K Batra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-07       Impact factor: 9.236

Review 4.  Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities.

Authors:  Zhiyong Wang; Gang Liu; Hairong Zheng; Xiaoyuan Chen
Journal:  Biotechnol Adv       Date:  2013-09-05       Impact factor: 14.227

5.  Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting.

Authors:  Simon Beaudoin; Michel Paquette; Laurent Fafard-Couture; Mylene A Tremblay; Roger Lecomte; Brigitte Guérin; Jeffrey V Leyton
Journal:  J Vis Exp       Date:  2018-03-08       Impact factor: 1.355

6.  Prospects of TAT-mediated protein therapy for fragile X syndrome.

Authors:  Surya A Reis; Rob Willemsen; Leontine van Unen; Andre T Hoogeveen; Ben A Oostra
Journal:  J Mol Histol       Date:  2004-05       Impact factor: 2.611

7.  The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters.

Authors:  P A Wender; D J Mitchell; K Pattabiraman; E T Pelkey; L Steinman; J B Rothbard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

8.  Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin.

Authors:  Leslie N Johnson; Siobhan M Cashman; Sarah Parker Read; Rajendra Kumar-Singh
Journal:  Vision Res       Date:  2009-09-03       Impact factor: 1.886

9.  Chemical modification allows phallotoxins and amatoxins to be used as tools in cell biology.

Authors:  Jan Anderl; Hartmut Echner; Heinz Faulstich
Journal:  Beilstein J Org Chem       Date:  2012-11-27       Impact factor: 2.883

Review 10.  Targeting the Tumour: Cell Penetrating Peptides for Molecular Imaging and Radiotherapy.

Authors:  Veerle Kersemans; Bart Cornelissen
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.